title: Reply to "Predictable Superiority of Everolimus-Eluting Stent Over Paclitaxel-Eluting Balloon in Patients with In-Stent Restenosis".
authors.affiliation: Madrid, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Alfonso
authors.affiliation: Madrid, Spain.
authors.forename: María J
authors.initials: MJ
authors.lastname: Pérez-Vizcayno
authors.affiliation: Madrid, Spain.
authors.forename: Bruno
authors.initials: B
authors.lastname: García Del Blanco
authors.affiliation: Madrid, Spain.
authors.forename: Arturo
authors.initials: A
authors.lastname: García-Touchard
authors.affiliation: Madrid, Spain.
authors.forename: Mónica
authors.initials: M
authors.lastname: Masotti
authors.affiliation: Madrid, Spain.
authors.forename: José R
authors.initials: JR
authors.lastname: López-Minguez
mesh_terms: D023903:Coronary Restenosis; D054855:Drug-Eluting Stents; D000068338:Everolimus; D006801:Humans; D017239:Paclitaxel; D015607:Stents
chemical_list: D000068338:Everolimus; D017239:Paclitaxel